JNJ Stock: Is the Rally Running Out of Steam?
A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.
Johnson & Johnson (JNJ), the healthcare company whose products span from advanced cancer therapies to surgical robotics, has been on a tear. The stock has rewarded investors with a 53% return over the last twelve months, a clear sign of momentum. But the pace has suddenly slowed. The stock has recently cooled, slipping roughly 4% from a multi-year high of $278.43 set earlier this month.
This pause puts every potential buyer on the spot. It forces the essential momentum question for a stock whose trend strength still ranks in the top 11% of large U.S. companies: the run is real, but is there anything left for a buyer at this price?
What’s Fueling This $643 Billion Machine?
A run like this needs a powerful engine, and Johnson & Johnson’s is built on elite profitability. The company’s operating margin over the last twelve months is 27%, comfortably above the S&P 500 median of 18.7%. Its operating cash flow margin tells a similar story, at 28% versus the market’s 22% median. The narrative extends beyond the stock market, telling a story of a high-quality business converting sales into cash with superior efficiency.
The primary driver is the Innovative Medicine division. More broadly, management highlighted that excluding the impact of biosimilar competition for STELARA, Johnson & Johnson’s total enterprise grew by double digits for the quarter, well ahead of its 5.6% reported operational growth. Blockbuster drugs like the cancer treatment DARZALEX grew close to 18%, while the immunology therapy TREMFYA posted 71% sales growth in the last quarter. Still, the overall picture requires perspective: the company’s total revenue over the last twelve months grew 8.1%, versus an S&P 500 median revenue growth of 8.3%.
The Market Sees the Quality, But Does It Overcharge for It?
The ticket for this quality costs a premium. Johnson & Johnson trades at a price-to-earnings multiple of 30.6, well above the S&P 500 median of 22.9. The price-to-sales multiple of 6.6 also stands at more than double the market median. The market is not blind to the company’s operational strength and is charging accordingly.
The honest catch for a buyer today isn’t valuation alone, but a mix of operational friction and lingering legal overhang. On the courtroom front, J&J continues to navigate persistent talc liabilities—marked by a recent $10 million mesothelioma verdict in Louisiana even as it pursues a broader proposed resolution for ovarian cancer claims. Inside the business itself, MedTech growth slowed to 3.6%, weighed down by cardiovascular weakness where management conceded results were ‘not to our standards’—including a 2% decline at Abiomed. Together, these unresolved legal liabilities and targeted operational drags represent the real-world friction threatening the stock’s momentum.
What Will Decide if the MedTech Drag Matters?
The entire investment case now balances on a simple question: can the pharma engine outrun the MedTech drag? The company’s leadership believes it can. Despite the softness, management recently raised its full-year guidance, now expecting operational sales growth for 2026 to land in the range of 6.5%-7.1%.
The single most important thing for investors to watch is whether the next quarterly report shows the MedTech segment, particularly cardiovascular, stabilizing. Proving it can hit that newly raised guidance, even with one of its key divisions underperforming, will be the ultimate test of whether this runner still has room to go. For investors who prefer to bet on the entire healthcare theme rather than a single name, a broad-based healthcare ETF like XLV offers another way to participate.
For more runs powered by rising forecasts rather than pure sentiment, our Guidance Momentum screen surfaces exactly those setups, daily.
Ride The Winners Without Betting On Just One
High-quality businesses with durable competitive advantages have historically formed the foundation of long-term portfolios. The hard part is that any single run can end abruptly, and a rider concentrated in one name feels every stumble at full force.
The Trefis High Quality (HQ) Portfolio holds roughly 30 businesses with the same DNA you just read about, strong margins, real cash generation, sound balance sheets, sized and re-balanced with rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Enjoy this runner; own the whole stable.